Crossmark

Decoding the Potential Impact of Plasma hsa-miR-24-3p and hsa-miR-181 d-3p Expression, Plasma IFN-γ Levels, and IFNG rs2069727 T/C Genetic Variant on Multiple Sclerosis Risk and Glatiramer Acetate Treatment

Crossref DOI link: https://doi.org/10.1007/s12035-025-05027-9

Published Online: 2025-06-02

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kalmaz, Mekselina https://orcid.org/0000-0003-0746-3502
Mungan, Semra https://orcid.org/0000-0002-6469-5185
Demirdöğen, Birsen Can https://orcid.org/0000-0002-1536-6123
Funding

Funding for this research was provided by:

Türkiye Bilimsel ve Teknolojik Araştırma Kurumu (121S345, 121S345, 121S345)

TOBB University of Economics and Technology
License Information

Text and Data Mining valid from 2025-06-02

Version of Record valid from 2025-06-02
More Information

Article History

Received: 24 July 2024

Accepted: 2 May 2025

First Online: 2 June 2025

Declarations

:

: Subjects were recruited from the Ankara Bilkent City Hospital, Neurology Outpatient Clinic, Ankara, Turkey. Approval of the study was obtained from the hospital ethics committee (date: May 26, 2021, decision no: E1-21–1805). Written informed consent was obtained from all participants. The study was conducted in accordance with the principles of the Declaration of Helsinki. The authors affirm that all human research participants provided informed consent for the publication of their clinical and demographic data anonymously.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below